Drugs / nb-Paclitaxel
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04167774 | Jul 2019 → Jun 2022 | non-small cell lung carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nb-Paclitaxel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04167774 ↗ |
| Route | Intravenous | “nb-Paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 260mg/m2 for 4-6 cycles.” NCT04167774 ↗ |